{"commentary":{"count":26,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":14,"podcast":10,"x_thread":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04871282\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"RINGSIDE","nct_id":"NCT04871282","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ringside-nct04871282. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"RINGSIDE","arms":[{"description":"AL102 1.2 mg","label":"Part A Main Study 1.2 mg daily","type":"EXPERIMENTAL"},{"description":"AL102 2 mg","label":"Part A Main Study 2 mg Intermittent","type":"EXPERIMENTAL"},{"description":"AL102 4 mg","label":"Part A Main Study 4 mg Intermittent","type":"EXPERIMENTAL"},{"description":"AL102, recommended dose regimen from Part A, 1.2 mg daily","label":"Part B AL102","type":"EXPERIMENTAL"},{"description":"Placebo to match recommended dose regimen from Part A","label":"Part B Placebo","type":"PLACEBO_COMPARATOR"},{"description":"AL102, recommended dose regimen from Part A, 1.2 mg daily","label":"Open Label Extension","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-12","type":"ESTIMATED"},"conditions":["Desmoid","Desmoid Tumor"],"enrollment":{"count":198,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"AL102","type":"DRUG"},{"name":"Placebo","type":"OTHER"}],"last_update":"2026-06-08","lead_sponsor":"Immunome, Inc.","official_title":"RINGSIDE: A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients With Progressing Desmoid Tumors","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2025-12-03","type":"ACTUAL"},"primary_outcomes":[{"measure":"Part A: Safety and Tolerability - Adverse Events","timeFrame":"Approximately 1.5 years"},{"measure":"Part B: Progression free survival (PFS)","timeFrame":"Approximately 2 years"}],"references":[],"start_date":{"date":"2021-09-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of AL102 in Patients With Progressing Desmoid Tumors","url":"https://clinicaltrials.gov/study/NCT04871282"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ringside-nct04871282"}